MALE BREAST CARCINOMA: A CASE REPORT

2021 ◽  
pp. 226-227
Author(s):  
Sarvesh Kumar Dubey ◽  
Subham Anand ◽  
D. K. Sinha ◽  
Aravind. K.R
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Positive Family History ◽  
Age Distribution ◽  
Male Breast ◽  
Age At Diagnosis ◽  
Prognostic Indicators ◽  
Lymph Node Status ◽  
Breast Cancers ◽  
Predisposing Factor

Male breast cancer(MBC) is a rare disease and represents less than 1% of all malignancies in men and only 1% of all breast cancers. The mean age at diagnosis for men with breast carcinoma is older than the average age at diagnosis for women. It has a unimodal age frequency distribution that peaks at age distribution of 71 years. MBC behaves in a way similar to post menopausal breast cancer in women. The main predisposing factor is a positive family history of breast cancer. 90% tumors are ER positive. The most important prognostic indicators are stage at diagnosis and lymph node status.

scholarly journals Correlation of Breast cancer Prognostic and Predictive indicators in Saudi patients: A 20 years retrospective observational study.

2020 ◽  
Author(s):  
Haitham Kussaibi
Keyword(s):  
Breast Cancer ◽  
Molecular Subtype ◽  
Age Distribution ◽  
Negative Relationship ◽  
University Hospital ◽  
Prognostic Indicators ◽  
Published Data ◽  
Breast Cancers ◽  
Luminal A ◽  
Saudi Patients

Introduction Breast cancer is the most common cancer in women in Saudi Arabia and the world (WHO 2020). Several studies have been published, worldwide, about the prognostic indicators of breast cancer, many of them showed a characteristic distribution according to certain geographical areas Methods Over 20 years (1998-2018), the results of 498 patients diagnosed with breast cancer, have been collected from the archive of the pathology department at King Fahd University Hospital (KFHU). Results This study included 498 patients diagnosed with breast cancer at King Fahd University Hospital over 20 years period (1998-2018), 58.4% (n=291) were Saudis. Data analysis showed a wide age distribution of breast cancers among eastern Saudi patients; however, most cases were seen in the 3rd and 4th decades. Luminal B was the most common subtype followed by triple-negative and luminal-A. Statistical analysis revealed a significant negative relationship between Saudi patients' age at diagnosis and Her2 expression (P= .030), interestingly, this association was not significant in none-Saudi patients (P= .528). Discussion/Conclusion. Our data revealed that breast cancer in Eastern Province had similar prognostics to international findings, however, Her2 profile and molecular subtype among Eastern Saudi women showed a minor deviation from worldwide published data.

Changing trends in HER-2 neu positive breast cancers in women: A study by a medical student and his preceptor.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12509-e12509
Author(s):  
Aaron Monga ◽  
Chaya Prasad ◽  
Rama Prasad ◽  
Rita Alcantara
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Metastatic Breast ◽  
The United States ◽  
Histologic Grade ◽  
Prognostic Indicators ◽  
Lymph Node Status ◽  
Low Grade ◽  
Breast Cancers ◽  
Her 2

e12509 Background: Breast cancer affects 3.5 million women in the United States with 155, 000 women living with metastatic breast cancer in the US with 40,290 deaths every year. In particular, HER-2 NEU positive lesions are aggressively malignant, with increased recurrence and decreased survival but good response to Herceptin. This study reviews trends of breast cancers and looks in depth into prognostic indicators, in HER-2 NEU positive breast cancers. Methods: Anonymized medical data including demographics and tumor characteristics from San Antonio Regional Hospital’s (SARH) tumor registry database were collected from 2015-2017. Inclusion criteria included female patients with a diagnosis of invasive breast cancers. Data was stratified according to age at diagnosis, race of the patient, histologic grade, size of the tumor, lymph node status, HER-2 NEU status and stage (pathologic and clinical). Results: From 2015 to 2017 we identified 371 patients with invasive breast cancers. The percentages of HER-2 NEU positive patients in these years was 15.7%, 16.0%, and 9.4% in 2015, 2016 and 2017 respectively. This represented a 6.6% drop in HER-2 NEU positive patients from 2016 to 2017. We then looked at all HER-2 NEU positive breast cancers. In 2017, 71% of patients with HER-2 NEU positive tumors presented with a low pathologic size compared to 36% in 2016 and 44% in 2015, and 29% presented with low histologic grade compared to 14% in 2016 and 12% in 2015, and 0% of patients presented with lymph node metastases compared to 18% in 2016 and 20% in 2015. Overall 100% of patients with HER-2 NEU positive tumors presented at a low stage compared to 73% in 2016 and 52% in 2015. Conclusions: Our data shows a decrease in HER-2 NEU positive cancers from 2015 to 2017. It is important to note that these HER-2 NEU lesions were associated with, smaller pathologic size, lower histologic grade, lower incidence of lymph node involvement and lower clinical stage. The identification of this subset of low grade, low stage HER-2 NEU positive tumors may be attributed to newer imaging modalities such as digital tomosynthesis and more aggressive preventive screening measures. These sensitive screening techniques may ensure a good clinical outcome.

scholarly journals Tumor collagen framework from bright-field histology images predicts overall survival of breast carcinoma patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Mindaugas Morkunas ◽  
Dovile Zilenaite ◽  
Aida Laurinaviciene ◽  
Povilas Treigys ◽  
Arvydas Laurinavicius
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Cox Regression ◽  
Regional Lymph Node ◽  
Histological Grade ◽  
Biological Information ◽  
Lymph Node Status ◽  
Bright Field

AbstractWithin the tumor microenvironment, specifically aligned collagen has been shown to stimulate tumor progression by directing the migration of metastatic cells along its structural framework. Tumor-associated collagen signatures (TACS) have been linked to breast cancer patient outcome. Robust and affordable methods for assessing biological information contained in collagen architecture need to be developed. We have developed a novel artificial neural network (ANN) based approach for tumor collagen segmentation from bright-field histology images and have tested it on a set of tissue microarray sections from early hormone receptor-positive invasive ductal breast carcinoma stained with Sirius Red (1 core per patient, n = 92). We designed and trained ANNs on sets of differently annotated image patches to segment collagen fibers and extracted 37 features of collagen fiber morphometry, density, orientation, texture, and fractal characteristics in the entire cohort. Independent instances of ANN models trained on highly differing annotations produced reasonably concordant collagen segmentation masks and allowed reliable prognostic Cox regression models (with likelihood ratios 14.11–22.99, at p-value < 0.05) superior to conventional clinical parameters (size of the primary tumor (T), regional lymph node status (N), histological grade (G), and patient age). Additionally, we noted statistically significant differences of collagen features between tumor grade groups, and the factor analysis revealed features resembling the TACS concept. Our proposed method offers collagen framework segmentation from bright-field histology images and provides novel image-based features for better breast cancer patient prognostication.

scholarly journals Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Jane Bayani ◽  
Coralie Poncet ◽  
Cheryl Crozier ◽  
Anouk Neven ◽  
Tammy Piper ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Univariate Analysis ◽  
Gene Signature ◽  
Male Breast ◽  
Risk Scores ◽  
Breast Cancers ◽  
Academic Risk ◽  
Genomic Grade Index ◽  
Prognostic Utility

AbstractMale breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, however, there are limited data on the utility of these tests in male BCa. Here we present the gene expression results of 381 M0, ER+ve, HER2-ve male BCa patients enrolled in the Part 1 (retrospective analysis) of the International Male Breast Cancer Program. Using a custom NanoString™ panel comprised of the genes from the commercial risk tests Prosigna®, OncotypeDX®, and MammaPrint®, risk scores and intrinsic subtyping data were generated to recapitulate the commercial tests as described by us previously. We also examined the prognostic value of other risk scores such as the Genomic Grade Index (GGI), IHC4-mRNA and our prognostic 95-gene signature. In this sample set of male BCa, we demonstrated prognostic utility on univariate analysis. Across all signatures, patients whose samples were identified as low-risk experienced better outcomes than intermediate-risk, with those classed as high risk experiencing the poorest outcomes. As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.

Male Versus Female Breast Cancers

2003 ◽  
Vol 127 (1) ◽  
pp. 36-41 ◽  
Author(s):  
D. Muir ◽  
R. Kanthan ◽  
S. C. Kanthan
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Male Breast Cancer ◽  
Male Breast ◽  
High Grade ◽  
Breast Cancers ◽  
Receptor Status ◽  
Female Breast ◽  
Grade 3

Abstract Context.—The rate of male breast cancer is a small fraction of that observed in females, thus severely limiting our understanding of the pathogenesis of this condition. It remains unclear whether the biological behavior and tumor progression associated with male breast cancer parallel that of the female form. Objectives.—To evaluate the immunohistochemical profile of male breast carcinomas and to compare this profile with that of stage-matched female breast cancers. Design.—Seventy-five cases of primary male breast cancer were identified using the records of the Saskatchewan Cancer Foundation over a period of 26 years (1970–1996). Fifty-nine of these cases had formalin-fixed, paraffin-embedded tissue blocks available for the purposes of this study. All cases were reviewed and a standardized modified Bloom-Richardson grading criterion was applied. Estrogen receptor status, progesterone receptor status, c-Erb-B2 expression, p53 expression, and Bcl-2 expression were evaluated by immunohistochemistry. Results from 240 consecutive cases of stage-matched female breast cancers analyzed in the same laboratory were used as a standard set for comparison. Results.—Male breast cancers tended to be high grade (85% grade 3) in comparison with the female breast cancers (50% grade 3). In descriptive analysis across all stages of disease, male carcinomas were more frequently estrogen receptor positive (81% vs 69%) than their female counterparts. Despite their high grade, they were less likely to overexpress p53 (9% vs 28%) and Erb-B2 (5% vs 17%) than the female counterparts. There was no significant difference in either progesterone receptor (63% vs 56%) or Bcl-2 (79% vs 76%) overexpression. Stratified analysis by stage-matched controls showed no statistically significant differences among the men and women with stage I disease. However, in stage II–matched samples, statistically significant differences were observed between the 2 groups. The male cancers were more likely to overexpress estrogen receptor (81.6% vs 64.4%, P = .04), progesterone receptor (71.1% vs 47.5%, P = .01), and Bcl-2 (78.9% vs 69.4%, P = .20). They also showed statistically significant lower expression of p53 (7.9% vs 36.3%, P = .001) and Erb-B2 (5.3% vs 23.8% P = .01). Conclusion.—Male breast cancers display distinct immunophenotypic differences from those occurring in women, implying a different pathogenesis in the evolution and progression of this disease. Such differences may play key roles in therapeutic management, warranting different treatment strategies in comparison to female breast cancers.

scholarly journals Male Breast Cancer- Report of Two Cases

1970 ◽  
Vol 21 (1) ◽  
pp. 80-82
Author(s):  
M Dayem Uddin ◽  
ABM Abdul Hannan
Keyword(s):  
Breast Cancer ◽  
Clinical Manifestation ◽  
Male Breast Cancer ◽  
Signs And Symptoms ◽  
Male Breast ◽  
Breast Cancers ◽  
Early Signs ◽  
Bangladeshi Population

Male breast cancer is rare. It accounts for 0.2% of all cancers, and 1% all breast cancers. Most patients present late for several reasons, including the absence of early signs and symptoms, and reduced awareness of the existence of such pathology among patients and physicians, Reporting these cases from among the Bangladeshi population, we tried to observe any differences in clinical manifestation from those reported in the literature, and aimed to increase the value assigned to male breast as a source of pathology among patients and physicians as well.   doi: 10.3329/taj.v21i1.3226 TAJ 2008; 21(1): 80-82

scholarly journals Expression of CD4, CD8 Biomarkers in Invasive Carcinoma of Breast with Clinicopathological Correlation

2021 ◽  
pp. 65-73
Author(s):  
C. Divyapriya ◽  
Aarthi Kannan ◽  
Vijayashree Raghavan
Keyword(s):  
Breast Cancer ◽  
T Lymphocytes ◽  
Invasive Breast Cancer ◽  
Triple Negative ◽  
Invasive Carcinoma ◽  
Tumour Size ◽  
Breast Cancer Subtype ◽  
Lymph Node Status ◽  
Breast Cancers ◽  
Cd8 T Lymphocytes

Introduction: Tumor infiltrating lymphocytes (TILs) are widely considered a key sign of the immune interaction between host and tumor, and potentially prognostic biomarkers of good or bad outcome in various cancers, including invasive breast cancer (IBC). Aim and Objectives: To correlate the expression of CD4, CD8 T-lymphocytes in invasive carcinoma breast with established markers of prognosis like tumour size, grade, lymph node status and molecular subtypes mainly ER, PR, Her 2Neu, Ki67 status, mainly the triple negative breast cancers(TNBC). Methodology: 58 Invasive breast carcinoma proven tissue blocks were subjected to immunohistochemistry and morphometric analysis for positive CD4, CD8 T-lymphocytes were done. Results:  Triple negative breast cancer subtype shows high TILs than other pathologic subtypes. Tumor interface CD8+ cells very well correlated with the pathological higher nodal stage. Majority CD4, CD8 positive cells were populated more towards the stromal and interface of the tumor microenvironment rather thatintratumoral. Conclusion: CD4+ and CD8+ counts may be a valuable independent prognostic tool in predicting the outcome in invasive breast cancer.

scholarly journals A case report of 29 year old male patient with breast carcinoma: diagnosed on fine needle aspiration cytology

2019 ◽  
Vol 8 (1) ◽  
pp. 375
Author(s):  
Komal Patel ◽  
Pallavi Chaudhri ◽  
Siddhi M. Patel
Keyword(s):  
Breast Cancer ◽  
Fine Needle Aspiration ◽  
Histopathological Examination ◽  
Needle Aspiration ◽  
Male Breast ◽  
Breast Cancers ◽  
Aspiration Cytology ◽  
Fine Needle ◽  
The Mean ◽  
Needle Aspiration Cytology

Breast cancer has been considered a female dominated disease. Carcinoma of male breast is a rare disease representing 1% of all breast cancers and less than 1 % of all cancers in men. The mean age at presentation is mainly in sixties. We here present a case of male breast cancer presented at very young age of 29 years, diagnosed on fine needle aspiration which was confirmed later on histopathological examination.

scholarly journals Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy

Breast Care ◽  
2019 ◽  
Vol 15 (1) ◽  
pp. 14-21 ◽  
Author(s):  
Francesca Pellini ◽  
Eleonora Granuzzo ◽  
Silvia Urbani ◽  
Sara Mirandola ◽  
Marina Caldana ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Family History ◽  
High Risk ◽  
Male Breast Cancer ◽  
Brca2 Mutation ◽  
Positive Family History ◽  
Male Breast ◽  
Mutation Carriers ◽  
History Of ◽  
Clinical Records

Background: Male breast cancer (MBC) is a rare disease with a rising incidence trend. The major risk factors related to MBC are a positive family history of breast cancer (BC) and BRCA1/2 mutations, which indicate a relevant genetic role. Methods: In this retrospective series, we enrolled 69 male patients presenting with male breast cancer (MBC) between 01/01/1992 and 31/12/2018, and 26 high-risk not-affected men presenting between 01/01/2016 and 31/12/2018. Participants’ electronic clinical records were reviewed. Patients’ data reported age at diagnosis, tumor characteristics, therapeutic management, and BRCA1/2 status as well as a family history of breast, ovarian, or prostate cancer (PCa) in first-degree relatives. Results: We analyzed 69 MBC patients. Median age was 64 years. The majority of tumors diagnosed were of an early TNM stage. The most frequent histological subtype was invasive ductal carcinoma (76.7%). Hormone receptors were positive in >90% of MBC cases. Nearly all patients underwent modified radical mastectomy or total mastectomy. Adjuvant endocrine therapy was delivered in 59.4%. Among MBC-affected patients, we recorded a high percentage of a positive family history of BC. Mutational analysis for the BRCA1/2 genes was performed in 17 MBC patients; 11.8% were carriers of BRCA2 pathogenic mutations. Among 26 healthy high-risk subjects included in this case series, 4 were BRCA1 mutation carriers and 9 were BRCA2 mutation carriers. Discussion: We evaluated the distribution of clinicopathological characteristics in MBC subjects and assessed the frequency of mutations in the BRCA genes in affected patients and healthy high-risk subjects, with the aim of proposing a surveillance program for BC and PCa.

Sign in / Sign up

Export Citation Format

Share Document